A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

Part of paid clinical trials in Tampa, Florida.

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Study ID
NCT00762255
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vorinostat — DRUG
    Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
  • Bevacizumab — DRUG
    Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
  • Irinotecan — DRUG
    Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.

Study Details

The purpose of the this study is to see if an investigations cancer treatment called vorinostat can be combined with the irinotecan/bevacizumab regimen safely.

Key Dates

Start date
Sep 30, 2008
Status verified
Jul 2013
Primary completion
Jul 31, 2013
Completion
Jul 31, 2013

Study Design

Enrollment
19 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A - Phase I Dose Escalation
    Dose Escalation - Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle. Vorinostat is given orally on days 1-7 and 15-21 of each cycle.
  • Experimental: B - Treatment at Maximum Tolerated Dose (MTD)
    MTD - Treatment at maximum tolerated dose

Primary Outcome Measure

Maximum Tolerated Dose (MTD) [ Time Frame: 25 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
H. Lee Moffitt Cancer Center & Research Institute, Inc.TampaFlorida33612-

Find similar trials in Tampa, FL

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
H. Lee Moffitt Cancer Center & Research Institute, Inc.· Tampa, FL

Related Studies